JP5512894B2 - ２−置換−８−アルキル−７−オキソ−７，８−ジヒドロピリド［２，３ｄ］ピリミジン−６−カルボニトリル及びその使用 - Google Patents

２−置換−８−アルキル−７−オキソ−７，８−ジヒドロピリド［２，３ｄ］ピリミジン−６−カルボニトリル及びその使用 Download PDF

Info

Publication number
JP5512894B2
JP5512894B2 JP2013523185A JP2013523185A JP5512894B2 JP 5512894 B2 JP5512894 B2 JP 5512894B2 JP 2013523185 A JP2013523185 A JP 2013523185A JP 2013523185 A JP2013523185 A JP 2013523185A JP 5512894 B2 JP5512894 B2 JP 5512894B2
Authority
JP
Japan
Prior art keywords
compound
cancer
formula
pyrimidine
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013523185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538196A5 (enExample
JP2013538196A (ja
Inventor
イー・プレムクマル・レディー
エム・ヴィ・ラマナ・レディー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple Univ School of Medicine
Original Assignee
Temple Univ School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple Univ School of Medicine filed Critical Temple Univ School of Medicine
Publication of JP2013538196A publication Critical patent/JP2013538196A/ja
Publication of JP2013538196A5 publication Critical patent/JP2013538196A5/ja
Application granted granted Critical
Publication of JP5512894B2 publication Critical patent/JP5512894B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013523185A 2010-08-05 2011-07-21 ２−置換−８−アルキル−７−オキソ−７，８−ジヒドロピリド［２，３ｄ］ピリミジン−６−カルボニトリル及びその使用 Expired - Fee Related JP5512894B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37094610P 2010-08-05 2010-08-05
US61/370,946 2010-08-05
PCT/US2011/044807 WO2012018540A1 (en) 2010-08-05 2011-07-21 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidine-6-carbonitriles and uses thereof

Publications (3)

Publication Number Publication Date
JP2013538196A JP2013538196A (ja) 2013-10-10
JP2013538196A5 JP2013538196A5 (enExample) 2014-03-13
JP5512894B2 true JP5512894B2 (ja) 2014-06-04

Family

ID=45559737

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013523185A Expired - Fee Related JP5512894B2 (ja) 2010-08-05 2011-07-21 ２−置換−８−アルキル−７−オキソ−７，８−ジヒドロピリド［２，３ｄ］ピリミジン−６−カルボニトリル及びその使用

Country Status (17)

Country Link
US (1) US8987267B2 (enExample)
EP (1) EP2600719B1 (enExample)
JP (1) JP5512894B2 (enExample)
KR (1) KR101434841B1 (enExample)
CN (1) CN103200822B (enExample)
AU (1) AU2011286282B2 (enExample)
BR (1) BR112013002375B1 (enExample)
CA (1) CA2807498C (enExample)
DK (1) DK2600719T3 (enExample)
EA (1) EA022527B1 (enExample)
ES (1) ES2525866T3 (enExample)
IL (1) IL224555A (enExample)
MX (1) MX2013001427A (enExample)
NZ (1) NZ606281A (enExample)
PL (1) PL2600719T3 (enExample)
PT (1) PT2600719E (enExample)
WO (1) WO2012018540A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2600719E (pt) * 2010-08-05 2014-12-22 Univ Temple 8 ¿ alquilo -2 - substituído 7 ¿ oxo ¿ 7,8 ¿ diidropirido [2,3 ¿ d] pirimidina ¿ 6 ¿ carbonitrilos e seus usos
WO2014031571A1 (en) * 2012-08-21 2014-02-27 Icahn School Of Medicine At Mount Sinai Treatment of viral infections
EP2968331B1 (en) 2013-03-14 2020-07-01 Icahn School of Medicine at Mount Sinai Pyrimidine compounds as kinase inhibitors
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
EP3172214B1 (en) 2014-07-26 2020-05-13 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
CN104447739B (zh) * 2014-11-07 2016-02-17 郑州泰基鸿诺药物科技有限公司 一种氘代Palbociclib衍生物、制备方法及应用
CN104496983B (zh) 2014-11-26 2016-06-08 苏州明锐医药科技有限公司 一种帕博西尼的制备方法
CN104447743B (zh) 2014-11-26 2016-03-02 苏州明锐医药科技有限公司 帕博西尼的制备方法
CN104478874B (zh) * 2014-12-08 2016-03-02 新发药业有限公司 一种帕博赛布的制备方法
CN104610254B (zh) * 2015-01-26 2017-02-01 新发药业有限公司 一种帕博赛布的低成本制备方法
CN105111205B (zh) * 2015-09-12 2017-01-04 山东罗欣药业集团股份有限公司 一种帕博西尼的制备方法
IL267299B (en) 2016-12-16 2022-09-01 Cstone Pharmaceuticals Cdk4/6 inhibitor
AU2019220746A1 (en) 2018-02-15 2020-08-27 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
KR102286701B1 (ko) * 2018-09-28 2021-08-06 재단법인 대구경북첨단의료산업진흥재단 피리도[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
TWI818930B (zh) * 2018-11-12 2023-10-21 美商昂可諾法治療股份有限公司 8-環戊基-7-側氧基-2-(4-哌嗪-1-基-苯基胺基)-7,8-二氫-吡啶[2,3-d]嘧啶-6-氰基及其用於治療增生性疾病的用途
JP7378167B2 (ja) * 2018-11-12 2023-11-13 オンコノバ セラピューティクス インコーポレイテッド ８‐シクロペンチル‐７‐オキソ‐２‐（４‐ピペラジン‐１‐イル‐フェニルアミノ）‐７，８‐ジヒドロ‐ピリド［２，３‐ｄ］ピリミジン‐６‐カルボニトリル及び同化合物の増殖性障害の治療における使用
US20220220103A1 (en) * 2018-12-28 2022-07-14 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US20230048132A1 (en) * 2018-12-28 2023-02-16 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
AU2020300586A1 (en) * 2019-07-02 2022-02-17 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
US20230132667A1 (en) * 2020-05-28 2023-05-04 University Of Washington Drug-like molecules and methods for the therapeutic targeting of viral rna structures
IL312506A (en) 2021-11-08 2024-07-01 Progentos Therapeutics Inc Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2023091724A1 (en) * 2021-11-18 2023-05-25 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
AU2022389984A1 (en) * 2021-11-18 2024-06-13 Traws Pharma, Inc. Methods and compositions for treating cancer
WO2023230288A1 (en) * 2022-05-25 2023-11-30 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
EP4618992A1 (en) * 2022-11-17 2025-09-24 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
EE200000706A (et) * 1998-05-26 2002-06-17 Warner-Lambert Company Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
HUP0203803A3 (en) 2000-01-27 2004-09-28 Warner Lambert Co Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
EP1261327B1 (en) * 2000-02-25 2005-04-27 F.Hoffmann-La Roche Ag Adenosine receptor modulators
CA2401368A1 (en) 2000-03-06 2001-09-27 Warner-Lambert Company 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
PL218692B1 (pl) 2002-01-22 2015-01-30 Warner Lambert Co Podstawiony 2-(pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-on oraz jego zastosowanie do leczenia zaburzenia lub stanu spowodowanego nieprawidłową proliferacją komórek
EP1718645A1 (en) 2004-02-18 2006-11-08 Warner-Lambert Company LLC 2-(pyridin-3-ylamino)-pyrido 2,3-d pyrimidin-7-ones
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
US20060142312A1 (en) 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
RU2007128961A (ru) * 2004-12-30 2009-02-10 4 Аза Ип Ив (Be) ПИРИДО(3,2-d)ПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ, ПОЛЕЗНЫЕ ДЛЯ КОНСЕРВАТИВНОГО ЛЕЧЕНИЯ
GB0428475D0 (en) 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
WO2006135993A1 (en) * 2005-06-24 2006-12-28 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c.
JP5480503B2 (ja) * 2005-10-07 2014-04-23 エクセリクシス， インク． ＰＩ３Ｋαのピリドピリミジノン型阻害剤
HRP20130902T1 (hr) * 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
EP2046322A4 (en) 2006-08-02 2010-10-06 Univ Temple ARYL-VINYL-SULFIDE, -SULFONE, -SULFOXIDE AND -SULFONAMIDES, DERIVATIVES THEREOF AND THERAPEUTIC APPLICATIONS THEREOF
WO2008047307A1 (en) 2006-10-16 2008-04-24 Gpc Biotech Inc. Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
WO2008150260A1 (en) 2007-06-06 2008-12-11 Gpc Biotech, Inc. 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
JP5797664B2 (ja) 2009-12-18 2015-10-21 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ 置換ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン及びそれらの治療用の使用
PT2600719E (pt) * 2010-08-05 2014-12-22 Univ Temple 8 ¿ alquilo -2 - substituído 7 ¿ oxo ¿ 7,8 ¿ diidropirido [2,3 ¿ d] pirimidina ¿ 6 ¿ carbonitrilos e seus usos

Also Published As

Publication number Publication date
EA022527B1 (ru) 2016-01-29
AU2011286282B2 (en) 2014-08-21
PL2600719T3 (pl) 2015-03-31
CN103200822A (zh) 2013-07-10
EP2600719A4 (en) 2014-01-01
BR112013002375A2 (pt) 2016-05-24
NZ606281A (en) 2014-09-26
MX2013001427A (es) 2013-06-13
US8987267B2 (en) 2015-03-24
IL224555A (en) 2016-03-31
BR112013002375B1 (pt) 2020-05-12
ES2525866T3 (es) 2014-12-30
KR101434841B1 (ko) 2014-08-29
AU2011286282A1 (en) 2013-02-14
EP2600719A1 (en) 2013-06-12
EP2600719B1 (en) 2014-10-08
EA201390199A1 (ru) 2013-07-30
PT2600719E (pt) 2014-12-22
CN103200822B (zh) 2014-12-24
CA2807498C (en) 2017-02-07
JP2013538196A (ja) 2013-10-10
KR20130098314A (ko) 2013-09-04
DK2600719T3 (da) 2014-12-15
CA2807498A1 (en) 2012-02-09
US20130131058A1 (en) 2013-05-23
WO2012018540A1 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
JP5512894B2 (ja) ２−置換−８−アルキル−７−オキソ−７，８−ジヒドロピリド［２，３ｄ］ピリミジン−６−カルボニトリル及びその使用
CN104546846B (zh) 1H‑吡唑并[3,4‑b]吡啶及其治疗应用
JP6704421B2 (ja) Ｄｎａアルキル化剤
JP2002513025A (ja) 胃酸分泌を阻害するイミダゾピリジン誘導体
WO2006069525A1 (en) Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof
CN109311865B (zh) 抗乙肝病毒的吡唑-噁唑烷酮类化合物
CN112457295B (zh) 具有Axl与c-Met激酶抑制活性的化合物及其制备和应用
TW200916458A (en) Heterocyclic compounds and methods of use thereof
EP3162801B1 (en) Salt of halogen-substituted heterocyclic compound
CN102712649B (zh) 苯并咪唑衍生物及其药物组合物和应用
IL209568A (en) Process for preparing 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1h)-one and derivatives thereof
KR20240006641A (ko) Tyk2 억제제로서의 헤테로아릴 화합물, 이의 조성물 및 용도
JP5797664B2 (ja) 置換ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン及びそれらの治療用の使用
TW202214564A (zh) 雙功能化合物及其使用方法
JP2018527331A (ja) 新規な縮合したピリミジノン及びトリアジノン誘導体、それらの調製方法、並びに抗真菌薬及び／又は抗寄生虫薬としてのそれらの治療での使用
CN118164983A (zh) 一种β-咔啉并[1',2':1,2]咪唑衍生物及其制备方法和应用、药物组合物
WO2013104829A1 (en) Novel arylamide derivatives having antiandrogenic properties
EA047161B1 (ru) Соединение, обладающее ингибирующей активностью в отношении киназ axl и c-met, его получение и его применение
HK1143590A1 (en) Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
HK1143590B (en) Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
WO2016180247A1 (zh) 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140127

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20140127

TRDD Decision of grant or rejection written
A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20140218

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140326

R150 Certificate of patent or registration of utility model

Ref document number: 5512894

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees